Metabolic and cardiorespiratory effects of decreasing lung hyperinflation with budesonide/formoterol in COPD: a randomized, double-crossover, placebo-controlled, multicenter trial

MLA

Miguel J. Divo, et al. “Metabolic and Cardiorespiratory Effects of Decreasing Lung Hyperinflation with Budesonide/Formoterol in COPD: A Randomized, Double-Crossover, Placebo-Controlled, Multicenter Trial.” Respiratory Research, vol. 21, no. 1, Jan. 2020, pp. 1–9. EBSCOhost, https://doi.org/10.1186/s12931-020-1288-3.

APA

Miguel J. Divo, Michael R. DePietro, John R. Horton, Cherie A. Maguire, & Bartolome R. Celli. (2020). Metabolic and cardiorespiratory effects of decreasing lung hyperinflation with budesonide/formoterol in COPD: a randomized, double-crossover, placebo-controlled, multicenter trial. Respiratory Research, 21(1), 1–9. https://doi.org/10.1186/s12931-020-1288-3

Chicago

Miguel J. Divo, Michael R. DePietro, John R. Horton, Cherie A. Maguire, and Bartolome R. Celli. 2020. “Metabolic and Cardiorespiratory Effects of Decreasing Lung Hyperinflation with Budesonide/Formoterol in COPD: A Randomized, Double-Crossover, Placebo-Controlled, Multicenter Trial.” Respiratory Research 21 (1): 1–9. doi:10.1186/s12931-020-1288-3.